Sir Chris Hoy’s interview with last week’s Sunday Times in which he said that doctors had told him that he had between two ...

Research uncovers how P-stalk ribosomes regulate cytokine responses, driving immune evasion in tumors across multiple cancer ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK ... Michael Dickinson, MBBS, FRACP, Lead of the Aggressive Lymphoma Disease Group at Peter ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration ...

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

The adoptive transfer of chimeric antigen receptor (CAR) T-cells has achieved remarkable therapeutic responses ... like cytokine release syndrome and neurotoxicity, as commonly seen in treated cancer ...

Antibodies show promise as candidates for therapeutics as well as tools for advancing mechanistic studies of the HER family receptors.

The first patient has been successfully imaged, marking a milestone in the development of this copper-based ...